

THE LANCET

Rheumatology

Supplementary appendix

This appendix formed part of the original submission. We post it as supplied by the authors.

Supplement to: Ferri C, Giuggioli D, Raimondo V, et al. COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study. *Lancet Rheumatol* 2021; published online Jan 12. [https://doi.org/10.1016/S2665-9913\(21\)00007-2](https://doi.org/10.1016/S2665-9913(21)00007-2).

Appendix.

Table 1.
Epidemiology of prevalence of Covid-19 in 1,636 Italian patients with systemic sclerosis (SSc)

	Pts n.	definite Covid-19+	P* OR value 95% CI	highly suspected Covid-19+	P* OR value 95% CI	total Covid-19+	P* OR value 95% CI
SSc	1636	14/1636 (0.85%)		47/1636 (2.87%)		61/1636 (3.72%)	
Vs			0.0010		<0.0001		<0.0001
Italian gen. population	100000	349/100000 (0.34%)	2.465 1.441-4.214		8.446 6.203-11.498		11.059 8.387-14.581
SSc Lombardy	315	7/315 (2.22%)		16/315 (5.07%)		23/315 (7.30%)	
Vs			0.0100		<0.0001		<0.0001
Lombardy gen. population	100000	739/100000 (0.73%)	3.053 1.438-6.480		7.188 4.324-11.947		10.580 6.878-16.274
Covid-19+ and SSc in Italian macro-areas							
SSc Nord	753	11/753 (1.46%)		29/753 (3.8%)		40/753 (5.3%)	
Vs			0.0020		<0.0001		<0.0001
Nord gen. population	100000	591/100000 (0.59%)	2.494 1.367-4.547		6.737 4.608-9.851		9.436 6.794-13.107
SSc Center	374	1/374 (0.3%)		10/374 (2.7%)		11/374 (2.9%)	
Vs			0.720		<0.0001		<0.0001
Center gen. population	100000	187/100000 (0.18%)	1.431 0.200-10.239		14.664 7.698-27.933		16.175 8.729-29.970
SSc Sud	509	2/509 (0.4%)		8/509 (1.6%)		10/509 (1.9%)	
Vs			0.0070		<0.0001		<0.0001
Sud gen. population	100000	70/100000 (0.07%)	5.631 1.377-23.026	22.796 10.912-47.622	22.796 10.912-47.622		28.609 14.663-55.819

**Mantel-Haenszel test*; *p* is significant, <0.05 SSc: systemic sclerosis; SSc Nord macro-area: Lombardy, Piemonte, Veneto, Emilia Romagna, and Liguria; SSc Center macro-area: Tuscany, Marche, and Lazio; SSc Sud macro-area: Campania, Molise, Puglia, Calabria, and Sicily. Mantel-Haenszel text and Odds Ratio (OR) were calculated by Java-Stat 2-way Contingency Table Analysis. STATA, and StatView were also used to evaluate other variables (data are expressed as mean±2SD).

Table 2.**Prevalence of Covid-19 in SSc patients, in relation to clinical features and therapies.**

	Pts n.	definite Covid-19+	P* OR value 95% CI	highly suspected Covid-19+	P* OR value 95% CI	total Covid-19+	P* OR value 95% CI
SSc lung inv. +	511	10/511 (1.9%)		23/511 (4.5%)		33/511 (6.4%)	
Vs			0.0010		0.0080		<0.0001
SSc lung inv. -	1125	4/1125 (0.4%)	5.594 1.746-17.921	24/1125 (2.1%)	2.153 1.204-3.853	28/1125 (2.5%)	2.705 1.616-4.526
Low dose aspirin -	1166	11/1166 (0.9%)		42/1166 (3.6%)		53/1166 (4.5%)	
Vs			0.544		0.0050		0.0060
Low dose aspirin+	470	3/470 (0.6%)	1.483 0.412-5.338	5/470 (1.0%)	3.475 1.366-8.839	8/470 (1.7%)	2.750 1.297-5.829

**Mantel-Haenszel test; p is significant, <0.05*

SSc: systemic sclerosis

Mantel-Haenszel test and Odds Ratio (OR) were calculated by Java-Stat 2-way Contingency Table Analysis. STATA, and StatView were also used to evaluate other variables (data are expressed as mean±2SD).

Supplementary References

1. Xie M, Chen Q. Insight into 2019 novel coronavirus - an updated interim review and lessons from SARS-CoV and MERS-CoV. *Int J Infect Dis* 2020; **94**: 119–24.
2. Antonelli A, Elia G, Ferrari SM, et al. The Covid-19, Epidemiology, Clinic and Prevention. *Curr Genomics* 2020; **21**: 157–60.
3. WHO. Coronavirus disease 2019 (COVID-19) situation report – 51, 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf?sfvrsn=1ba62e57_10 [Accessed by Mar 11, 2020].
4. Lake MA. What we know so far: COVID-19 current clinical knowledge and research. *Clin Med (Lond)* 2020; **20**: 124–7.
5. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA* 2020; **323**: 1061–9.
6. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med* 2020; **382**: 1708–20.
7. Memoli MJ, Athota R, Reed S, et al. The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts. *Clin Infect Dis* 2014; **58**: 214–24.
8. Lu C, Li S, Liu Y. Role of immunosuppressive therapy in rheumatic diseases concurrent with covid-19. *Ann Rheum Dis* 2020; **79**: 737–9.
9. Gianfrancesco MA, Hyrich KL, Gossec L, et al. Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. *Lancet Rheumatol* 2020; **2**: e250–3.

10. Ferro F, Elefante E, Baldini C, et al. COVID-19: the new challenge for rheumatologists. *Clin Exp Rheumatol* 2020; **38**: 175–80.
11. Sarzi-Puttini P, Giorgi V, Sirotti S, et al. COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? *Clin Exp Rheumatol* 2020; **38**: 337–42.
12. Favalli EG, Ingegnoli F, Cimaz R, Caporali R. What is the true incidence of COVID-19 in patients with rheumatic diseases? *Ann Rheum Dis* 2020; [Epub ahead of print].
13. Ferri C, Giuggioli D, Raimondo V, et al. COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series. *Clin Rheumatol* 2020; 1–10.
14. Bozzalla Cassione E, Zanframundo G, Biglia A, Codullo V, Montecucco C, Cavagna L. COVID-19 Infection in a northern-Italian Cohort of Systemic Lupus Erythematosus Assessed by Telemedicine. *Ann Rheum Dis* 2020; **79**: 1382–3.
15. Tomelleri A, Sartorelli S, Campochiaro C, Baldissera EM, Dagna L. Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: a monocentric survey. *Ann Rheum Dis* 2020; **79**: 1252–3.
16. Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. *Lancet* 2020; **395**: 1771–8.
17. Mihai C, Dobrota R, Schröder M, et al. COVID-19 in a Patient With Systemic Sclerosis Treated With Tocilizumab for SSc-ILD. *Ann Rheum Dis* 2020; **79**: 668–9.
18. Avouac J, Airó P, Carlier N, Matucci-Cerinic M, Allanore Y. Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab. *Ann Rheum Dis* 2020; [Epub ahead of print].
19. EULAR Textbook on Rheumatic Diseases, 3rd edition, 2018. Ed. Johannes WJ Bijlsma and Eric Hachulla. BMJ Publishing Group. 2018. United Kingdom. ISBN:978-0-7279-1882-6.

20. Ferri C, Giuggioli D, Guiducci S, et al. Systemic sclerosis Progression INvestiGation (SPRING) Italian registry: demographic and clinico-serological features of scleroderma spectrum. *Clin Exp Rheumatol* 2020; **38 Suppl 125**: 40–7.
21. Riccardo F, Andrianou X, Bella A, et al. Integrated surveillance of COVID-19 in Italy (Epidemia COVID-19); Istituto Superiore di Sanità (ISS), Roma. Updating April 28, 2020; published April 30, 2020. Available from: <https://www.epicentro.iss.it/en/coronavirus/sars-cov-2-national-surveillance-system>.
22. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7). (Released by National Health Commission & National Administration of Traditional Chinese Medicine on March 3, 2020). *Chin Med J (Engl)* 2020; **133**: 1087–95.
23. Matucci-Cerinic M, Bruni C, Allanore Y, et al. Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management. *Ann Rheum Dis* 2020; **79**: 724–6.
24. Sardu C, Gambardella J, Morelli MB, Wang X, Marfella R, Santulli G. Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence. *J Clin Med* 2020; **9**: 1417.
25. Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. *N Engl J Med* 2020; **383**: 120–8.
26. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. *Lancet* 2020; **395**: 1417–8.
27. Bellan M, Parisi S, Stobbione P, et al. Impact of the Covid-19 outbreak on an Italian cohort of systemic sclerosis patients. *Scand J Rheumatol* 2020; 1–2.
28. Zen M, Fuzzi E, Astorri D, et al. SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: A cross-sectional study on 916 patients. *J Autoimmun* 2020; **112**: 102502.
29. Webster P. Virtual health care in the era of COVID-19. *Lancet* 2020; **395**: 1180–1.

30. Ferri C, Giuggioli D, Raimondo V, Fallahi P, Antonelli A, on behalf of the COVID-19 & ASD Italian Study Group. COVID-19 in Italian patients with rheumatic autoimmune systemic diseases. *Ann Rheum Dis* 2020; [Epub ahead of print].
31. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet* 2020; **395**: 1033–4.
32. Wise J. Covid-19: Risk of second wave is very real, say researchers. *BMJ* 2020; **369**: m2294.
33. Flaxman S, Mishra S, Gandy A, et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. *Nature* 2020; **584**: 257–61.
34. Hsiang S, Allen D, Annan-Phan S, et al. The effect of large-scale anti-contagion policies on the COVID-19 pandemic. *Nature* 2020; **584**: 262–7.
35. Toscano G, Palmerini F, Ravaglia S, et al. Guillain-Barré Syndrome associated with SARS-CoV-2. *N Engl J Med* 2020; **382**: 2574–6.
36. Alberti P, Beretta S, Piatti M, et al. Guillain-Barré syndrome related to COVID-19 infection. *Neurol Neuroimmunol Neuroinflamm* 2020; **7**: e741.
37. Viner RM, Whittaker E. Kawasaki-like disease: emerging complication during the COVID-19 pandemic. *Lancet* 2020; **395**: 1741–3.
38. Shah S, Danda D, Kavadichanda C, Das S, Adarsh MB, Negi VS. Autoimmune and rheumatic musculoskeletal diseases as a consequence of SARS-CoV-2 infection and its treatment. *Rheumatol Int* 2020; **40**: 1539–54.
39. Denton CP, Khanna D. Systemic sclerosis. *Lancet* 2017; **390**: 1685–99.
40. Roncati L, Ligabue G, Fabbiani L, et al. Type 3 Hypersensitivity in COVID-19 Vasculitis. *Clin Immunol* 2020; **217**: 108487.
41. Ferri C, Zignego AL, Pileri SA. Cryoglobulins. *J Clin Pathol* 2002; **55**: 4–13

42. Zakrzewska K, Arvia R, Torcia MG, et al. Effects of Parvovirus B19 In Vitro Infection on Monocytes from Patients with Systemic Sclerosis: Enhanced Inflammatory Pathways by Caspase-1 Activation and Cytokine Production. *J Invest Dermatol* 2019; **139**: 2125–33.e1.
43. Arcangeletti MC, Maccari C, Vescovini R, et al. A Paradigmatic Interplay between Human Cytomegalovirus and Host Immune System: Possible Involvement of Viral Antigen-Driven CD8+ T Cell Responses in Systemic Sclerosis. *Viruses* 2018; **10**: 508.
44. Ferri C, Artoni E, Sighinolfi GL, et al. High serum levels of silica nanoparticles in systemic sclerosis patients with occupational exposure: Possible pathogenetic role in disease phenotypes. *Semin Arthritis Rheum* 2018; **48**: 475–81.